Your browser version may not work well with NCBI's Web applications. More information here...
1: Pediatr Nephrol. 1997 Aug;11(4):418-22.Click here to read Links

A controlled study of deflazacort in the treatment of idiopathic nephrotic syndrome.

Broyer M, Terzi F, Lehnert A, Gagnadoux MF, Guest G, Niaudet P.

Département de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Paris, France.

Forty patients with steroid-dependent idiopathic nephrotic syndrome (INS), a mean follow-up of 5.5 years, and a mean number of relapses of ten were blindly assigned to either deflazacort (DFZ) (n = 20) or prednisone (PDN) (n = 20) according to a ratio of equivalence of DFZ/ PDN = 0.8. This treatment was given for 1 year. The number of relapses was significantly lower in patients receiving DFZ. After 1 year, 12 remained in remission with DFZ compared with 2 with PDN. Growth velocity was not different in the two groups. Bone mineral content, assessed by quantitative computed tomography of L1 L2 vertebrae, decreased after 1 year by 6% in the DFZ group versus 12% in the PDN group (NS). The mean body weight increase of +3.9 +/- 4.1 kg in the PDN group was higher than that of the DFZ group, +1.7 +/- 2.8 kg (P = 0.06). Cushingoid symptoms tended to be less after 12 months in the DFZ group. In conclusion, this study shows that DFZ was more effective than PDN in limiting relapses in steroid-dependent INS, and that cushingoid symptoms, weight gain, and decrease in bone mineral content tended to be less marked with this drug than with PDN.

PMID: 9260237 [PubMed - indexed for MEDLINE]

Patient Drug Information

  • Prednisone (Prednisone Intensol® , Sterapred® , Sterapred® DS)

    Prednisone is used alone or with other medications to treat the symptoms of low corticosteroid levels (lack of certain substances that are usually produced by the body and are needed for normal body functioning). Prednis...

  • Source: AHFS Consumer Medication Information